| Our total sales recorded
for the year 2007-08 was Rs. 6770 million. Our sales in India contribute
to 66% of our total business. We rank 21st in the Indian Pharmaceutical
Industry (Source: ORG; March 2008) with leadership positions in
several product categories.
| Therapeutic segments covered in India |
- Diabetes
- Cardiovascular
- Orthopaedics
- Nutritional
- Respiratory
- Dermatology
- Gynaecology
- Paediatrics
- CNS
|
- Overall rank in the Indian pharma industry is 21
|
- Leader in Diabetes & Cardiology in terms of
prescription generation.
|
- Presence in Dermatology with leading brand from Europe
|
- Presence in Nutritionals, Respiratory, Gynaecology
through innovative products from partners in USA and
Europe
|
|
We lead the oral anti-diabetic segment in India in terms of value
as well as prescriptions. We have maintained a leadership position
in this segment for almost two decades. 34% of our sales are contributed
by the anti-diabetic portfolio, which includes insulin.
We lead in the cardiovascular disease segment in terms of prescription
generation. In terms of value, we rank amongst the first 10 companies
in India. The cardiology portfolio contributes 30% to our sales.
Presence in Respiratory, Nutritionals, Orthopaedics and Gynaecology
segments is attributed to innovative products through partnerships
with companies from Europe and USA.
We have a significant presence in Dermatology with a leadership
position in the anti-acne segment. We have recently launched Sebamed range of skin-care products from Europe.
USV also ventured into CNS segment with the launch of a new division to cater the needs of Neurologists and Psychiatrists.
To ensure focus and growth in all the relevant
therapeutic areas, we have 7 marketing and sales teams that operate
as 7 business units: Condor • Corvette • Pharma • Centra • Conquer • Celesta and Cosmeceutical.
The Celesta division is a new addition to USV Family to exclusively focus on the needs of Corporate Hospitals.
|
